A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.

被引：0

作者：

Omuro, Y.

Ikari, T.

Ishii, H.

Ozaka, M.

Suyama, M.

Matsumura, Y.

Itoi, T.

Egawa, N.

Yano, S.

Hanada, K.

Kimura, Y.

Ukita, T.

Ishida, Y.

Tani, M.

Ohoka, S.

Hirose, Y.

Hijioka, S.

Watanabe, R.

Ikeda, T.

Nakajima, T.

机构：

[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[2] Tobu Chiiki Hosp, Tokyo, Japan

[3] Canc Inst Hosp, Tokyo, Japan

[4] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan

[5] Juntendo Univ Hosp, Tokyo, Japan

[6] Tokyo Med Univ, Tokyo 1608402, Japan

[7] Kanazawa Univ, Kanazawa, Ishikawa, Japan

[8] JA Onomichi Gen Hosp, Hiroshima, Japan

[9] Sapporo Med Univ Hosp, Sapporo, Hokkaido, Japan

[10] Toho Univ, Ohashi Med Ctr, Tokyo, Japan

[11] Kurume Univ Hosp, Kurume, Fukuoka, Japan

[12] Wakayama Med Univ Hosp, Wakayama, Japan

[13] Tokyo Med & Dent Univ Hosp, Tokyo, Japan

[14] Fukui Red Cross Hosp, Fukui, Japan

[15] Kumamoto Red Cross Hosp, Kumamoto, Japan

[16] Matsuyama Shimin Hosp, Matsuyama, Japan

[17] Yokosuka Kyosai Hosp, Yokosuka, Kanagawa, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4029

引用

下载

页数：1

共 50 条

[1] Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
Ueno, Makoto
Ohkawa, Shinichi
Kobayashi, Noritoshi
Sugimori, Kazuya
Kawaguchi, Yoshiaki
Kobayashi, Satoshi
Taguri, Masataka
Yamanaka, Takeharu
Mine, Tetsuya
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[2] Retrospective Study of Gemcitabine plus S-1 versus Gemcitabine Alone in Cases with Unresectable Advanced Pancreatic Cancer
Suzuki, Shuji
Ozaki, Yuhi
Saida, Shin
Kaji, Satoshi
Koike, Nobusada
Harada, Nobuhiko
Hayashi, Tsuneo
Suzuki, Mamoru
HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 916 - 920
[3] Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
Sudo, Kentaro
Ishihara, Takeshi
Hirata, Nobuto
Ozawa, Fumiaki
Ohshima, Tadashi
Azemoto, Ryosaku
Shimura, Kenji
Nihei, Takeshi
Nishino, Takayoshi
Nakagawa, Akihiko
Nakamura, Kazuyoshi
Hara, Taro
Tada, Motohisa
Mikata, Rintaro
Tawada, Katsunobu
Yokosuka, Osamu
Nakaji, So
Yamaguchi, Taketo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 389 - 396
[4] Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
Kentaro Sudo
Takeshi Ishihara
Nobuto Hirata
Fumiaki Ozawa
Tadashi Ohshima
Ryosaku Azemoto
Kenji Shimura
Takeshi Nihei
Takayoshi Nishino
Akihiko Nakagawa
Kazuyoshi Nakamura
Taro Hara
Motohisa Tada
Rintaro Mikata
Katsunobu Tawada
Osamu Yokosuka
So Nakaji
Taketo Yamaguchi
Cancer Chemotherapy and Pharmacology, 2014, 73 : 389 - 396
[5] Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Ueno, Hideki
Ioka, Tatsuya
Ikeda, Masafumi
Ohkawa, Shinichi
Yanagimoto, Hiroaki
Boku, Narikazu
Fukutomi, Akira
Sugimori, Kazuya
Baba, Hideo
Yamao, Kenji
Shimamura, Tomotaka
Sho, Masayuki
Kitano, Masayuki
Cheng, Ann-Lii
Mizumoto, Kazuhiro
Chen, Jen-Shi
Furuse, Junji
Funakoshi, Akihiro
Hatori, Takashi
Yamaguchi, Taketo
Egawa, Shinichi
Sato, Atsushi
Ohashi, Yasuo
Okusaka, Takuji
Tanaka, Masao
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (13) : 1640 - +
[6] Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study
Ioka, T.
Ikeda, M.
Ohkawa, S.
Yanagimoto, H.
Fukutomi, A.
Sugimori, K.
Baba, H.
Yamao, K.
Shimamura, T.
Chen, J.
Mizumoto, K.
Furuse, J.
Funakoshi, A.
Hatori, T.
Yamaguchi, T.
Egawa, S.
Sato, A.
Ohashi, Y.
Cheng, A.
Okusaka, T.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[7] A phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.
Han, Boram
Kim, Hyeong Su
Choi, Dae Ro
Shim, Byoungyong
Lee, Kyung Hee
Kim, Jin Won
Kim, Jung Han
Kim, Jung Hoon
Song, Hunho
Park, Choong Kee
Moon, Sung Hoon
Kim, Jong Hyeok
Jeon, Jang Yong
Lee, Jung Woo
Zang, Dae Young
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[8] Prognostic index based on the phase III study of gemcitabine plus S-1, S-1 alone or gemcitabine alone in patients with advanced pancreatic cancer (GEST study)
Ueno, H.
Nagase, M.
Hamamoto, Y.
Egawa, S.
Ohkawa, S.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S462 - S462
[9] RANDOMIZED PHASE II TRIAL OF S-1 VERSUS S-1 PLUS OXALIPLATIN (SOX) IN PATIENTS WITH GEMCITABINE REFRACTORY PANCREATIC CANCER
Okusaka, T.
Ohkawa, S.
Isayama, H.
Fukutomi, A.
Yamaguchi, K.
Ikeda, M.
Funakoshi, A.
Nagase, M.
Nakamori, S.
Hamamoto, Y.
ANNALS OF ONCOLOGY, 2012, 23 : 241 - 242
[10] Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan
Fukutomi, Akira
Okusaka, Takuji
Sugimori, Kazuya
Ueno, Hideki
Ioka, Tatsuya
Ohkawa, Shinichi
Boku, Narikazu
Yamao, Kenji
Mizumoto, Kazuhiro
Furuse, Junji
Funakoshi, Akihiro
Hatori, Takashi
Yamaguchi, Taketo
Egawa, Shinichi
Sato, Atsushi
Ohashi, Yasuo
Cheng, Ann-Lii
Tanaka, Masao
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →